Biobanks and alternative energy resources

September 26, 2012

Last week I participated in HandsOn: Biobanks, an interactive conference exploring the values of biobanking. The warm and collaborative atmosphere made the conference a both moving and encouraging experience.

Here is how the conference made me think about the value of biobanks:

New techniques of fundamental importance to humanity tend to appear in proportion to our needs for them. Efforts to develop efficient uses of alternative energy resources, for example, were not seriously supported until we became truly aware of how the world’s oil finds were running dry.

My impression at the conference was that biobanks could be compared to a new and much needed global energy resource. Biobanks are presently being set up all over the world as part of a new infrastructure not only for medical research, but also for health care and the pharmaceutical industry.

And the point is that efficient uses of this alternative resource of biological material appear urgently needed in our current situation.

Health care costs run amok, and so does the industry’s costs for developing new drugs. An efficient infrastructure of biobank resources would very likely help us come to terms with the problems that accumulate in the old framework.

The industry wastes billions on medical hypotheses that after years of hard work turn out to be unfeasible. Translating research results into safe and efficient drugs often is more complex and time-consuming than the research itself. Using biobanks could speed up the translation of research into drugs and make the process more predictable.

The health care sector too has problems and needs to make its practices more efficient, for example, through personalized medicine. Increasingly clever uses of biobank resources allow researchers to begin answering questions like:

  • Who is in the risk category for developing prostate cancer?
  • Who responds to which treatment?
  • Who will experience side effects?
  • Who can be given a clean bill of health after cancer treatment?

Answering such questions is revolutionary in medicine. So revolutionary in fact, that the intelligent use of biobank resources promises to generate new definitions of health and disease; new notions of diagnosis, treatment, and preventive medicine.

Developing a global infrastructure of biobank resources is a challenge for biobankers. Two challenges that were discussed at the conference were harmonization and evidence-based sampling and storing techniques. I got the impression that these challenges were manageable.

However, seeing the real significance of the biological resources that are being collected in biobanks is a challenge also for politicians, legislators and ethicists. To approach the political, legal and ethical issues in the right spirit, I believe we need a bigger picture of our situation.

Perhaps the comparison to our present need to develop intelligent uses of alternative energy resources can provide such a picture.

Pär Segerdahl

Approaching future issues - the Ethics Blog


No consent for maintaining high-quality health care?

September 21, 2012

Collecting biological samples and health information from healthy donors in the construction of biobanks and research registers obviously requires the donors’ informed consent.

But is a similar demand for consent reasonable when patients provide their doctor with samples for diagnosis, undergo medical examination and treatment, and answer the doctor’s questions? Or can patients be expected to accept that their traces in the health care system – for example, data about experienced side effects – are monitored to optimize the quality of medical diagnosis and treatment?

A recent article by Mats G. Hansson at CRB discusses the issue. The article in Theoretical Medicine and Bioethics is well-argued and challenges common assumptions.

The basic argument is that quality registers and biobanks within the health care system play such a decisive role in optimizing the quality of the care that we expect as patients, that no consent should be required for collecting and studying our traces as patients (provided that the purpose is maintenance of high-quality health care, and nothing else).

Consent is associated with costs, in the form of drop-out of data. This impairs the value of the information in quality registers and biobanks, and thereby also the conditions for optimizing medical diagnosis and treatment.

Privacy is not the only ethical concern. Quality of care carries moral weight too.

Perhaps we are prepared to accept certain access to our patient histories, if such access is a precondition to maintaining and developing high standards of health care?

Pär Segerdahl

We recommend readings - the Ethics Blog


How unspecific is broad consent?

September 13, 2012

In response to an informative article on personalized medicine and biobanking in Nature Biotechnology, a recent letter to the Editor defends broad consent for biobanking.

The three letter writers emphasize the patient and donor perspective:

  • “…patient donors actually express concern that study-specific consent can be burdensome and impede research.”

Given these donors’ desire to give so-called broad consent, I want to highlight two problematic aspects of the distinction between specific and broad consent.

The first is that the word “broad” consent may give rise to the impression that the consent is so general and vague that it cannot be seen as informed consent to anything specific at all. But broad consent is not “broad” in such an absolute sense, akin to vagueness. It is “broad” only in a relative sense: in relation to the historically more prevalent case of consenting to individual research projects.

The distinction between specific and broad consent is a distinction between two ways of being specific. One of these ways of being specific dominated the scene first. It therefore functioned as a linguistic standard. The other way of being specific had to put up with being called “broad.”

Specific consent, then, is specific only in a specific sense: one that is historically conditioned and changeable. It is not the golden standard of exactitude. Consent can therefore be “broad” without being vague.

The second problematic aspect is that when people donate samples to biobanks, the exact nature of the individual research projects that might use their samples is less relevant to them than when they consent to invasive procedures in clinical trials.

The risks are minimal in biobank research. Donors therefore look more to the practical utility of the research than to the research itself. Forcing them to consider the purposes and questions and procedures of individual research projects is forcing them to attend to a level of medical research that is less relevant to them as donors.

In short, a historically and linguistically insensitive demand for “specific consent” in biobanking may hinder donors from giving the kind of specific consent they authentically want to give in this new but more and more prevalent context.

Pär Segerdahl

Minding our language - the Ethics Blog


Research for the sake of the patient

September 7, 2012

We regularly tell strangers about sensitive aspects of our lives. We do it every time we visit the doctor. We do it without hesitating, in spite of the fact that the information won’t stay with the doctor to whom we give it.

The information is archived and will be read by health care staff in the future, when we visit a hospital again. As patients, we are satisfied with this state of affairs. Typically, we are happy that our samples are saved for future use, and that research is being done on our data to improve the quality of the care.

It is obvious to us that these actions are taken for our sake as patients, or as future patients.

However, when the same kind of data is collected for similar overall purposes, but outside of the health care sector, in the construction of biobanks and registers for future medical research, it suddenly becomes more tempting to worry about the safety of our data.

In spite of the fact that the researchers’ information about us

  1. normally is less comprehensive than in the doctor’s journal,
  2. is coded so that the connection to us is as safe as in a bank vault,
  3. isn’t used to do research on us individually, but to explore human patterns of disease,

a tendency to imagine nightmarish scenarios of surveillance appears. – Why?

One reason could be an assumption that researchers only want to answer their own questions. They don’t do research for our sake. They are curious and need our support to realize their own research goals.

Another reason could be an assumption that if medical research has commendable purposes related to health and health care, these purposes are very general and societal: Improved Public Health; Decreased Health Care Costs; A Flourishing Pharmaceutical Sector etc.

Who cares about little me?

When I visit the doctor, the connection to my own health and care is obvious. When I donate blood to the biobank for future research, on the other hand, the connection to me as a patient, or as a future patient, is less obvious.

Still, today’s health care depends on yesterday’s research.

The information I give the doctor would not help me a bit as a patient, if millions had not already provided medical research with their data. My doctor wouldn’t even be able to suggest a diagnosis, or recommend an effective treatment.

I believe we need to defuse the issue of personal data in biobanks and research registers; calm down our tendency to think that the information is collected without regard to us, and for wholly different purposes than in health care. Even in research, our data are collected for our sake: so that we, the day we visit the hospital and tell the doctor about our troubles, can expect well-founded diagnoses and effective treatments.

If you want to reflect more about our interest as future patients that there is ongoing biobank and register research, I want to recommend a coming dissertation:

  • Biobank Research – Individual Rights and Public Benefit

Author is Joanna Stjernschantz Forsberg at CRB, who defends her dissertation the 6th of October in Uppsala.

I also want to recommend the interactive conference, HandsOn: Biobanks, in Uppsala 20-21 September, which tries to illuminate the values of biobanking. You can register for the conference until the 11th of September.

Pär Segerdahl

We challenge habits of thought : the Ethics Blog


%d bloggers like this: